Rhinology: Chronic Rhinosinusitis (CRS)
High-Yield Revision Notes for Board Review & PG Entrance Examinations
Chronic Rhinosinusitis (CRS) is a prolonged inflammatory condition of the nasal cavity and paranasal sinuses lasting for ≥12 consecutive weeks. Unlike acute rhinosinusitis, which is typically infectious, CRS is primarily a multi-factorial chronic inflammatory disease. It is broadly divided into two major phenotypic forms: CRSwNP (with Nasal Polyps) and CRSsNP (without Nasal Polyps).
1. Diagnostic Criteria & Investigations
Diagnosis requires the presence of ≥2 major clinical symptoms for at least 12 weeks, paired with objective evidence of mucosal inflammation.
Core Symptoms (At least one must be #1 or #2):
- Nasal blockade/obstruction/congestion.
- Anterior nasal discharge or posterior nasal drip (mucopurulent).
- Facial pain, pressure, or fullness.
- Hyposmia or anosmia (decreased/lost sense of smell; predominantly in adults).
Objective Evidence (Mandatory):
- Anterior Rhinoscopy / Endoscopy: Demonstrates polyps, purulent discharge from the middle meatus, or edematous mucosal obstruction.
- Non-Contrast CT of Paranasal Sinuses (Coronal View): **The gold standard imaging modality**. Key findings include mucosal thickening, ostiomeatal complex occlusion, or opacification of sinus cavities. (Plain X-rays have no diagnostic role in modern CRS management).
2. Phenotypic Phenotypes: CRSwNP vs. CRSsNP
| Feature | CRS with Nasal Polyps (CRSwNP) | CRS without Nasal Polyps (CRSsNP) |
|---|---|---|
| Prevalence | ~20% to 30% of CRS cases | ~70% to 80% of CRS cases (More common) |
| Dominant Symptom | Severe Anosmia / Hyposmia and persistent nasal obstruction. | Persistent Facial pain / Pressure and purulent post-nasal drip. |
| Immunological Profile | Type 2 Helper T-cell (Th2) response (IL-4, IL-5, IL-13) in Western countries. | Non-Type 2 response (Th1 / Th17 driven), featuring IFN-gamma and IL-17. |
| Cellular Infiltrate | Marked Eosinophilia | Predominantly Neutrophilic |
| Systemic Associations | Asthma, Samter’s Triad, Cystic Fibrosis, Allergic Fungal Rhinosinusitis (AFRS). | Anatomical obstructions (deviated septum), recurrent acute infections, smoking. |
| Primary Medical Therapy | Intranasal steroids, short-course systemic steroids, and targeted biologics. | Intranasal steroids, saline rinses, and prolonged low-dose macrolides. |
3. Pathophysiology Specifics & Endotypes
Modern rhinology classifies CRS by **endotypes** (underlying biological mechanisms) rather than just clinical appearance:
- Type 2 Inflammation (Eosinophilic): Characterized by high tissue eosinophil counts and elevated local IgE. Elevated IL-5 drives eosinophil survival, while IL-4 and IL-13 disrupt the epithelial tissue barrier. This process leads to the formation of multiple bilateral ethmoidal polyps.
- Non-Type 2 Inflammation (Neutrophilic): Associated with chronic bacterial colonization (e.g., Staphylococcus aureus biofilms or Pseudomonas in cystic fibrosis), which causes persistent mucosal thickening and fibrosis without forming true polypoid structures.
4. Comprehensive Management Strategy
Management is primarily medical, with surgery reserved for cases refractory to maximal medical treatment.
- First-Line Medical Therapy (Both types): High-volume nasal saline irrigations combined with daily Intranasal Corticosteroids (INCS) (e.g., Fluticasone propionate, Mometasone furoate). INCS reduce tissue edema, decrease polyp volume, and open sinus pathways.
- Advanced Medical Options for CRSwNP:
• Short-course Systemic Corticosteroids: (e.g., Oral Prednisolone for 1–2 weeks) to provide rapid reduction of extensive polyp burden (“medical polypectomy”).
• Biologics (Monoclonal Antibodies): Approved for severe, refractory Type 2 CRSwNP. These target specific points in the inflammatory cascade: Dupilumab (anti-IL-4Rα), Mepolizumab/Reslizumab (anti-IL-5), and Omalizumab (anti-IgE).
- Advanced Medical Options for CRSsNP: Prolonged courses (2–3 months) of low-dose macrolide antibiotics (e.g., Azithromycin or Clarithromycin) are sometimes utilized for their **immunomodulatory and anti-inflammatory properties**, rather than their direct bactericidal effects.
- Surgical Management: Indicated when formal medical options fail to control disease. The surgical standard is Functional Endoscopic Sinus Surgery (FESS). FESS clears obstructive polyps, opens the ostiomeatal complex, and unroofs affected ethmoid, maxillary, frontal, or sphenoid sinuses to restore natural ventilation and permit better delivery of topical spray medications.
5. High-Yield Allergic Fungal Rhinosinusitis (AFRS)
AFRS is a unique subtype of CRSwNP that frequently appears in board examination questions. It represents an allergic hypersensitivity response to non-invasive fungal hyphae (most commonly Bipolaris or Aspergillus species) within the sinus cavities.
- Bent and Kuhn Diagnostic Criteria:
1. True nasal polyposis (Type 2 eosinophilic driven).
2. Presence of thick, tenacious, pungent “allergic fungal mucin” (often described as resembling peanut butter).
3. Demonstration of fungal hyphae on Grocott’s methenamine silver (GMS) stain without tissue invasion.
4. Type I (IgE) hypersensitivity to fungi (confirmed via skin prick or specific serology).
5. Characteristically unilateral or asymmetric findings on CT scan.
- Classic CT Sign: “Double Density” sign on non-contrast CT. This displays central areas of hyperattenuation (caused by calcium and manganese salts concentrated by the fungal organisms) surrounded by peripheral low-attenuation areas of edematous inflamed mucosa.